ReShape Lifesciences (RSLS) Stock Statistics & Valuation Metrics

ReShape Lifesciences has a market cap or net worth of $4.74M. The enterprise value is $3.43M.

ReShape Lifesciences has 11,276,248 shares outstanding. The number of shares has decreased by -2.65% in one year.

ReShape Lifesciences’s return on equity (ROE) is 28.18 and return on invested capital (ROIC) is -913.44%.

The current PE Ratio of ReShape Lifesciences is -0.32. ReShape Lifesciences’s PEG ratio is <0.01.

In the last 12 months, ReShape Lifesciences had revenue of 8.01M and earned -7.13M in profits. Earnings per share was -13.83.

In the last 12 months, operating cash flow was -4.43M and capital expenditures 0.00, giving a free cash flow of -4.43M billion.

ReShape Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

ReShape Lifesciences upcoming earnings date is May 20, 2025, TBA Not Confirmed.

ReShape Lifesciences as a current ratio of 0.92, with Debt / Equity ratio of -382.21%

In the past 12 months, ReShape Lifesciences has paid 39.00K in taxes.

ReShape Lifesciences EV to EBITDA ratio is -0.39, with an EV/FCF ratio of -0.58.

ReShape Lifesciences has $693.00K in cash and marketable securities with ― in debt, giving a net cash position of $274.00K billion.

Gross margin is 63.17%, with operating margin of -83.29%, and net profit margin of -89.06%.

The average price target for ReShape Lifesciences is ―, which is 11.43% higher than the current price. The consensus rating is ―